Found: 154
Select item for more details and to access through your institution.
A phase 1 study of IDH305 in patients with IDH1<sup>R132</sup>-mutant acute myeloid leukemia or myelodysplastic syndrome.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 3, p. 1145, doi. 10.1007/s00432-022-03983-6
- By:
- Publication type:
- Article
Current status and research directions in acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01143-2
- By:
- Publication type:
- Article
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00981-4
- By:
- Publication type:
- Article
Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36933-y
- By:
- Publication type:
- Article
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
- Published in:
- Japanese Journal of Clinical Oncology, 2022, v. 52, n. 1, p. 29, doi. 10.1093/jjco/hyab170
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0686-1
- By:
- Publication type:
- Article
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1618, doi. 10.3390/ijms18081618
- By:
- Publication type:
- Article
Hereditary Predispositions to Myelodysplastic Syndrome.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 6, p. 838, doi. 10.3390/ijms17060838
- By:
- Publication type:
- Article
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22874-x
- By:
- Publication type:
- Article
Hematologic malignancies in Li–Fraumeni syndrome: A case report.
- Published in:
- American Journal of Medical Genetics. Part A, 2024, v. 194, n. 7, p. 1, doi. 10.1002/ajmg.a.63573
- By:
- Publication type:
- Article
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 1, p. 30, doi. 10.1111/bjh.19519
- By:
- Publication type:
- Article
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 6, p. 2259, doi. 10.1111/bjh.19446
- By:
- Publication type:
- Article
Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 3, p. 604, doi. 10.1111/bjh.18278
- By:
- Publication type:
- Article
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
- By:
- Publication type:
- Article
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1054, doi. 10.1111/bjh.17347
- By:
- Publication type:
- Article
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 3, p. 442, doi. 10.1111/bjh.14806
- By:
- Publication type:
- Article
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 3, p. 344, doi. 10.1111/bjh.13299
- By:
- Publication type:
- Article
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 10, p. 1959, doi. 10.1002/ajh.27435
- By:
- Publication type:
- Article
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 9, p. 1790, doi. 10.1002/ajh.27434
- By:
- Publication type:
- Article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Toward an improved understanding of hypomethylating agent and venetoclax therapies.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 2, p. 152, doi. 10.1002/ajh.27178
- By:
- Publication type:
- Article
Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1711, doi. 10.1002/ajh.27054
- By:
- Publication type:
- Article
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E233, doi. 10.1002/ajh.27005
- By:
- Publication type:
- Article
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. 1383, doi. 10.1002/ajh.26997
- By:
- Publication type:
- Article
DDX41 mutations in patients with non‐myeloid hematologic neoplasms.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. E193, doi. 10.1002/ajh.26952
- By:
- Publication type:
- Article
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 658, doi. 10.1002/ajh.26852
- By:
- Publication type:
- Article
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 493, doi. 10.1002/ajh.26816
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. E416, doi. 10.1002/ajh.26692
- By:
- Publication type:
- Article
A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1127, doi. 10.1002/ajh.26630
- By:
- Publication type:
- Article
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. E299, doi. 10.1002/ajh.26600
- By:
- Publication type:
- Article
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 8, p. 1035, doi. 10.1002/ajh.26601
- By:
- Publication type:
- Article
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 885, doi. 10.1002/ajh.26572
- By:
- Publication type:
- Article
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. 329, doi. 10.1002/ajh.26451
- By:
- Publication type:
- Article
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. 68, doi. 10.1002/ajh.26395
- By:
- Publication type:
- Article
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. 1420, doi. 10.1002/ajh.26314
- By:
- Publication type:
- Article
Post‐transplantation donor‐derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. E350, doi. 10.1002/ajh.26266
- By:
- Publication type:
- Article
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 914, doi. 10.1002/ajh.26206
- By:
- Publication type:
- Article
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 735, doi. 10.1002/ajh.26142
- By:
- Publication type:
- Article
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E154, doi. 10.1002/ajh.26122
- By:
- Publication type:
- Article
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 208, doi. 10.1002/ajh.26039
- By:
- Publication type:
- Article
Early detection of transformation to BPDCN in a patient with MDS.
- Published in:
- Experimental Hematology & Oncology, 2018, v. 7, n. 1, p. N.PAG, doi. 10.1186/s40164-018-0117-6
- By:
- Publication type:
- Article
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 1983, doi. 10.3390/cancers15071983
- By:
- Publication type:
- Article
Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1617, doi. 10.3390/cancers15051617
- By:
- Publication type:
- Article
Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions.
- Published in:
- Cancers, 2021, v. 13, n. 12, p. 2974, doi. 10.3390/cancers13122974
- By:
- Publication type:
- Article
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.
- Published in:
- Cancers, 2018, v. 10, n. 6, p. 187, doi. 10.3390/cancers10060187
- By:
- Publication type:
- Article
Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 1, p. 109, doi. 10.1111/ejh.13880
- By:
- Publication type:
- Article
Clonal Hematopoiesis: Malignant Implications, Extrahematologic Manifestations, and Management.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 7, p. 320
- By:
- Publication type:
- Article
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 14, p. 1, doi. 10.1002/cam4.70028
- By:
- Publication type:
- Article